GlassScriptPhysician profile
Robert Todd Lancaster
NPI 1093773673
$6,163.98
in general payments reported to CMS, 2019-2025
29 companies · $692 in 2025
The $692 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2021: $467 · 2022: $1,773 · 2023: $985 · 2024: $414 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $1,510.18 | 2019 | |
| Angiodynamics, INC. | $756.36 | 2022-2024 | Auryon Laser System 100-120 Vac |
| Endologix LLC | $638.49 | 2019-2025 | |
| Pfizer INC. | $505.81 | 2023-2025 | |
| Philips North America LLC | $505.33 | 2021-2024 | (Bh4) Igt Devices Undivided, (Az7) Lasers |
| Medtronic, INC. | $498.50 | 2022-2025 | Endurant Iis, Hawkone, Closurefast |
| Veryan Medical Incorporated | $272.42 | 2021-2025 | Biomimics 3d Vascular Stent System |
| Janssen Pharmaceuticals, INC | $216.07 | 2021-2024 | Xarelto |
| Cardiovascular Systems INC. | $197.80 | 2021 | |
| Silk Road Medical, INC. | $166.94 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Lemaitre Vascular, INC. | $140.78 | 2023-2025 | Artegraft Vascular Graft |
| Abbott Laboratories | $117.29 | 2023 | Diamondback Peripheral |
| Cordis US Corp. | $97.85 | 2023-2025 | Outback, Brite Tip Radianz, Avanti |
| Boston Scientific Corporation | $89.68 | 2022-2025 | Varithena Administration Pack, Embold Fibered |
| Amgen INC. | $71.66 | 2023 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.96 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $53.85 | 2023 | Xarelto |
| Smith+Nephew, INC. | $44.27 | 2023-2024 | Grafix Pl, Oasis, Stravix Pl |
| Livanova USA, INC. | $43.53 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Tactile Systems Technology INC | $29.61 | 2024 | Flexitouch Plus, Entre Plus |
| Abbvie INC. | $22.51 | 2022 | |
| Organogenesis INC. | $22.36 | 2022 | |
| Acera Surgical, INC. | $20.30 | 2024 | Restrata Wound Matrix |
| Cormedix INC. | $18.09 | 2024 | Defencath |
| Reprise Biomedical, INC. | $17.72 | 2023 | Miro3d |
| Cook Medical LLC | $15.45 | 2025 | Zenith Alpha |
| Medtronic Vascular, INC. | $15.00 | 2019 | |
| Surmodics, INC. | $12.17 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.